Oncological safety and functional outcomes of testosterone replacement therapy in symptomatic adult-onset hypogonadal prostate cancer patients following robot-assisted radical prostatectomy
| Autor: | Dean Elterman, Adel Arezki, Assaad El-Hakim, Kevin C. Zorn, Ahmed S. Zakaria, Hanna Shahine, David-Dan Nguyen, Marc Zanaty, Russel Schwartz, Félix Couture, Iman Sadri |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Nephrology Biochemical recurrence medicine.medical_specialty Multivariate analysis Hormone Replacement Therapy Urology medicine.medical_treatment 030232 urology & nephrology Logistic regression 03 medical and health sciences Prostate cancer Postoperative Complications 0302 clinical medicine Robotic Surgical Procedures Internal medicine medicine Clinical endpoint Humans Eunuchism Testosterone Aged Retrospective Studies Prostatectomy business.industry Prostatic Neoplasms Middle Aged medicine.disease Treatment Outcome 030220 oncology & carcinogenesis Cohort business |
| Zdroj: | World Journal of Urology. 39:3223-3229 |
| ISSN: | 1433-8726 0724-4983 |
| DOI: | 10.1007/s00345-020-03475-7 |
| Popis: | Testosterone replacement therapy (TRT) remains controversial in men with treated prostate cancer. We assessed its safety and functional impacts in patients after definitive surgical treatment with robotic-assisted radical prostatectomy (RARP). We performed a retrospective analysis of 1303 patients who underwent RARP during the years 2006–2019. We identified men with symptoms of andropause and low serum testosterone who received TRT post-RARP; then we divided the cohort into two groups accordingly for comparison. Biochemical recurrence (BCR) was the primary endpoint. Secondary endpoints included functional outcomes. Predictors of BCR, including the effect of TRT on BCR, were evaluated using univariable and multivariable logistic regression. Among the forty-seven men who received TRT, the mean age was 60.83 years with a median follow-up of 48 months. Three (6.4%) and 157 (12.56%) patients experienced BCR in TRT and non-TRT groups, respectively. Baseline characteristics were similar between both groups except for higher mean BMI in the TRT group (p = 0.03). In the multivariate analysis (MVA), higher pre-RARP prostate-specific antigen (PSA) (p = 0.043), higher International Society of Urological Pathology score (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink